Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Gra…

この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Gra…
この記事を読む
Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients. Alborelli I et al.Lung …
この記事を読む
Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small …
この記事を読む
SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic. Berghoff AS…
この記事を読む
Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression.Frank MS et alLung Cancer.…
この記事を読む
Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer Abravan A et al.J Thorac Oncol. 2…
この記事を読む
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, sin…
この記事を読む
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. Herbst RS et al.N Engl J Med. 2020 Oct 1;38…
この記事を読む
Osimertinib in Resected EGFR-Mutated Non-Small-CellLung Cancer. Wu YL et al.N Engl J Med. 2020 Sep 19.PMID:32955177. Abs…
この記事を読む
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 1…